ASCO data for Amgen’s acute leukemia drug disappoint, but path forward remains, experts say

Experts expressed dismay at single-agent data from the Phase I study, which a spokesperson noted was still in dose expansion. However, the drug could have a future in combinations or in patients with minimal disease left over after prior treatment.